Recent Updates
Recently added Catalysts

Upcoming Catalyst

Drug Pipeline Intelligence

Clinical Trial Results

Inside Trades

Options Data

News Section

Hedge Funds

Ownership Trends

Competitive Position

Monopar Therapeutics Inc.

35 indications, side-by-side phase, drug & LoA

$59.77

+0.68 (+1.14%)

D 32Pipeline Score Richly Valued Biotech · Clinical
Market Cap
422.84 M
EPS
-2.07
P/E Ratio
-
Value Trade
4.34 M
SEC Financials
Q1 2026

  • Dilution Risk

    5%

  • Revenue

    -

  • R&D Expenses

    3.49 M

  • Operating CF

    -3.47 M

  • Total Assets

    137.98 M

  • Total Liabilities

    2.59 M

  • Equity

    135.39 M

  • D/E Ratio

    12,345

5.8 %
Week
18.76 %
1 Month
15.63 %
3 Month
-23.53 %
6 Month
129.53 %
5 Year
51.19 %
All Time
Cash Data
Healthy

  • Cash Position

    104.91 M

  • Monthly Burn

    1.16 M

  • Runway

    89.7 mo

  • Burn Trend

    Stable

  • SEC Filing

    May 14, 2026
Overview
Volume
154.41 K
52 Week Range
28.40 - 105
% held by Insiders
38.17 %
% held by Institutions
81 %
Enterprise Value
285.48 M
Total Shares
6.68 M
Short %
38.48 %
Float Shares
4.10 M
Company Description
HQ: 1000 SKOKIE BLVD SUITE 350, WI...
Employees:22
https://www.monopartx.com

locked

Upcoming Catalyst
Catalyst Drug/Treatment Stage Probability of Approval Description Drug Type Therapeutic Area Source
NDA Submission example
ALXN1840 (tiomolibdate choline, TMC) Wilson disease, neurologic symptoms
NDA
—
Small Molecules
Nervous System
ALXN1840 (tiomolibdate choline, TMC) Wilson disease, neurologic symptoms
NDA
—
Small Molecules
Nervous System
ALXN1840 (tiomolibdate choline, TMC) Wilson disease, neurologic symptoms
NDA
—
Small Molecules
Nervous System
Unlock Upcoming Catalyst data
Drug Pipeline Intelligence
D32
Pipeline Score
$59M
Pipeline Value
Richly Valued
Valuation Signal
2
Drugs Scored
0.1x
rNPV / MCap
Top 36%
Micro Cap
(rank 580 of 905)
Percentile Rank
Monopar Therapeutics Inc. faces pipeline headwinds (32/100), with $294M risk-adjusted pipeline value, led by MNPR-101-PCTA-177Lu in Solid Tumor, Adult (Phase 1).
Showing 1 of 1 assets
DrugIndicationPhaseNCT IDPTRSrNPVStatusEnrollmentVelocityDesignCompletionML SignalLast Change
MNPR-101-DFO*-89Zr
Small molecule		Solid Tumor, AdultPhase 1NCT0633708410% $147M RECRUITING 12 STALLED D (26) Apr 1, 2026ELEVATED_RISKLOW
May 26, 2026
Unlock Drug Pipeline Intelligence
Clinical Trial Results
Drug Name Indications Phase Date Trial Results Summary Title Source
ALXN1840
Wilson disease
Phase 2
2025-09-24
ALXN1840
Wilson disease
Phase 2
2025-09-24
ALXN1840
Wilson disease
Phase 2
2025-09-24
Unlock Clinical Trial Results data
Inside Trades
TREND
CORPORATE INSIDERS BOUGHT SHARES WORTH 1.8M IN THE LAST 3 MONTHS
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Unlock Inside Trades data
Show Data
Hedge Funds
TREND
HEDGE FUNDS INCREASED HOLDINGS BY 200.0K SHARES IN THE LAST QUARTER
Shares Held
2040.00B1530.00B1020.00B510.00B0
Q3
2024
Q4
2024
Q1
2025
Q2
2025
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Fund Count
60%
Share Volume
25%
Conviction
15%
Hedge Funds invested in MNPR
HedgeFund Name
( 3 )
% of Portfolio Current MV
-
Shares Owned
-
Activity
Avg Price $0

Example Capital Management

2.5 %
15.00 M
250.00 K

Example Capital Management

2.5 %
15.00 M
250.00 K

Example Capital Management

2.5 %
15.00 M
250.00 K
Unlock Hedge Funds table data
Biotech Analyst Ratings
Symbol
Firm
Rating
Action
Price Target
Upside
date
MNPR
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
MNPR
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
MNPR
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
Unlock Biotech Analyst Ratings data
MNPR Stock Forecast & Analyst Consensus
BUY
Analyst Ratings
Buy65.0%
Hold25.0%
Sell10.0%
Price Target Trend
Average$24.00
Low$18.00
High$32.00
Unlock Price Target Trend
MNPR Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
ExpirationVolumeOpen InterestImplied Volatility CallsImplied Volatility Puts
CallsPutsPut-Call RatioCallsPutsPut-Call RatioIVOiWaIvVWaIvIVOiWaIvVWaIv
Unlock Option Chain Statistics data
Option Chain
CallsStrikePuts
Last PriceVolumeOpen InterestLast PriceVolumeOpen Interest
No data available
Unlock Option Chain data
Unlock Options Chart data
Open interest
0 600K 1.2M 1.8M Avg OI 1.00 M Open Interest
0 1 2 3 1.1 Put-Call Ratio
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
0 450K 900K 1.4M Avg OV 750.00 K Option Volume
0 1 2 3 0.95 Put-Call Ratio
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Latest Monopar Therapeutics Inc. (MNPR) News & Alerts
-
Saturday, June 13, 2026
(%)
+ More

Demo Biotech Announces Positive Phase 3 Results

Competitive Position
How MNPR ranks across every disease it competes in
Indication Rank Phase Best DrugTop 3 Competitors Market $B LoA Position
Gastric Cancer #30 of 49 PHASE 1 MNPR-101-PCTA-177Lu
AZN ONC JAZZ
$6.74B 0.76 FOLLOWER
Bladder Cancer #31 of 47 PHASE 1 MNPR-101-PCTA-177Lu
AZN BMY JNJ
$0.33B 0.76 FOLLOWER
Ovarian Cancer #43 of 61 PHASE 1 MNPR-101-PCTA-177Lu
MRK AZN LLY
$4.0B 0.76 FOLLOWER
Pancreatic Cancer #44 of 73 PHASE 1 MNPR-101-PCTA-177Lu
RVMD RCUS AZN
$3.7B 0.76 FOLLOWER
Breast Cancer #49 of 94 PHASE 1 MNPR-101-PCTA-177Lu
MRK AZN GILD
$10.85B 0.76 FOLLOWER
Colorectal Cancer #49 of 82 PHASE 1 MNPR-101-PCTA-177Lu
ABBV BMY MRK
$7.68B 0.76 FOLLOWER
Lung Cancer #56 of 79 PHASE 1 MNPR-101-PCTA-177Lu
MRK GILD AMGN
$28.1B 0.76 FOLLOWER